.png)
SummaryA Summary of Product Characteristics (SmPC) is the legally binding document, approved by a European regulatory authority as part of a medicine's marketing authorisation, that tells healthcare professionals how to prescribe and use that medicine safely and effectively. It is the official reference text for a medicinal product in the EU, its content and order are defined by Article 11 of Directive 2001/83/EC, and it is the source from which the patient package leaflet is derived. The abbreviation is sometimes written SPC.
That definition carries more weight than it first appears. The SmPC is not a summary in the ordinary sense, and it is not marketing material that a company writes about its own product. The European Commission's guideline puts it plainly: the SmPC "forms an intrinsic and integral part of the marketing authorisation" and "sets out the agreed position of the medicinal product as distilled during the course of the assessment process". A marketing authorisation holder cannot change a word of it without the approval of the competent authority that issued the authorisation.
This article explains what an SmPC contains, what legal instruments govern it, how it relates to the package leaflet and to the US Prescribing Information, the specific role it plays in pharmacovigilance, and why the document is increasingly treated as structured data rather than a PDF.
SmPC is the correct and preferred form. It is the abbreviation used by the European Medicines Agency and by the European Commission, whose guideline is titled "A Guideline on Summary of Product Characteristics (SmPC)".
SPC still circulates widely, for two reasons worth understanding. First, it was the older common abbreviation and it persists in legacy documentation and in some national practice. Second, and more importantly, SPC collides with Supplementary Protection Certificate, the patent term extension governed by Regulation (EC) No 469/2009. In a pharmaceutical context those two concepts sit close enough together that the ambiguity is a genuine problem, and the lowercase "m" was adopted to disambiguate them.
If you are writing for a regulatory audience, use SmPC. If you are searching a document archive, search for both.
Four instruments do the work:
Within the Common Technical Document, the SmPC sits in Module 1.3. The operative drafting guidance is the European Commission's Guideline on Summary of Product Characteristics, Revision 2, which has applied since 1 May 2010.
"The SmPC forms an intrinsic and integral part of the marketing authorisation." European Commission, Guideline on Summary of Product Characteristics
One boundary in that guideline is frequently overlooked and matters in practice: it is "not in the remit of the SmPC to give general advice on the treatment of particular medical conditions". The SmPC describes one product. It is not a therapeutic guideline, and reading it as one is a category error.
Here is the nuance that most sources get wrong. A standard SmPC has 10 numbered sections. Article 11 lists 12 headings in total, but sections 11 and 12 apply only to radiopharmaceuticals. Pages that state flatly that an SmPC "has 12 sections" are misleading you.
The sections, in the order Article 11 prescribes:
| Section | Title | Subsections and notes |
|---|---|---|
| 1 | Name of the medicinal product | Name, strength and pharmaceutical form |
| 2 | Qualitative and quantitative composition | Active substances and excipients with known effect |
| 3 | Pharmaceutical form | |
| 4 | Clinical particulars | The largest section, nine subsections: 4.1 Therapeutic indications, 4.2 Posology and method of administration, 4.3 Contraindications, 4.4 Special warnings and precautions for use, 4.5 Interaction with other medicinal products, 4.6 Fertility, pregnancy and lactation, 4.7 Effects on ability to drive and use machines, 4.8 Undesirable effects, 4.9 Overdose |
| 5 | Pharmacological properties | 5.1 Pharmacodynamic properties, 5.2 Pharmacokinetic properties, 5.3 Preclinical safety data |
| 6 | Pharmaceutical particulars | 6.1 List of excipients, 6.2 Incompatibilities, 6.3 Shelf life, 6.4 Special precautions for storage, 6.5 Nature and contents of container, 6.6 Special precautions for disposal and other handling |
| 7 | Marketing authorisation holder | |
| 8 | Marketing authorisation number(s) | |
| 9 | Date of first authorisation or renewal | |
| 10 | Date of revision of the text | Exists because the SmPC is versioned |
| 11 | Dosimetry | Radiopharmaceuticals only |
| 12 | Instructions for preparation of radiopharmaceuticals | Radiopharmaceuticals only |
Two details signal whether a source is current. Section 4.6 is "Fertility, pregnancy and lactation" in the current template; sources still showing "Pregnancy and lactation" are working from an outdated version. And the operative template is the QRD Product Information annotated template, currently version 10.4 (February 2024), with a draft version 11 issued for public consultation in April 2025.
A practical point that catches teams out: a separate SmPC is required for each pharmaceutical form and each strength. "The SmPC for product X" is often shorthand for a small family of documents.
Three documents make up what the regulation calls the product information, and they are annexed to the marketing authorisation:
The relationship between the first and the third is the part that matters operationally, and it is directional. The Commission guideline states that the package leaflet "shall be drawn up in accordance with the SmPC". The leaflet is derived from the SmPC, never the other way round. A change to the SmPC forces a corresponding change to the leaflet; a leaflet cannot introduce information that the SmPC does not support.
Teams that treat the two as parallel documents maintained side by side generate divergence, and divergence here is a compliance finding.
The closest US equivalent of an SmPC is the Prescribing Information, the PI or USPI, approved by the FDA. Both are the authoritative labelling document for healthcare professionals. They differ in almost every particular below that.
| Aspect | EU SmPC | US Prescribing Information (USPI) |
|---|---|---|
| Regulator | EMA and national competent authorities | FDA |
| Governing format | QRD template, Notice to Applicants Volume 2C | Physician Labeling Rule, mandatory in that format since 2006 |
| Structure | Numbered sections 1 to 10, plus 11 and 12 for radiopharmaceuticals | Highlights, Table of Contents, then Full Prescribing Information across 17 sections |
| Risk signalling | No Boxed Warning equivalent. Nearest analogue is section 4.4, plus the black inverted triangle where applicable | Boxed Warning, commonly called the black box |
| Legal status | Intrinsic part of the marketing authorisation, cannot change without authority approval | FDA-approved labeling |
One correction worth making explicitly, because the error is common and a regulatory affairs reader will spot it instantly: the black inverted triangle is not the European equivalent of a black box warning. The triangle means the medicine is subject to additional monitoring under Article 23 of Regulation (EC) No 726/2004, typically because it is new or because safety data are still limited. It is a statement about the state of knowledge, not a warning about severity of risk.
The substantive consequence for anyone working across both regions: identical clinical data can produce different labels. An event that the FDA categorises as a Warning may appear in the EU as a precaution in section 4.4, or elsewhere, because the two agencies assess and categorise independently. Cross-region label reconciliation is real work, not a translation exercise.
This is where the SmPC stops being a reference document and starts being an operational instrument, and it is the part least well explained elsewhere.
In pharmacovigilance, section 4.8, Undesirable effects, functions as reference safety information. It defines which adverse reactions are already known and accepted for a medicine. Safety teams assess each incoming adverse event report against section 4.8 to determine expectedness: a reaction listed there is expected, and a reaction not listed there is unexpected. That single determination drives expedited reporting obligations, and in the clinical trial setting it is the hinge on which a suspected unexpected serious adverse reaction turns.
Two structural complications follow.
The first is divergence between the company core data sheet and the approved SmPC. A marketing authorisation holder maintains a CCDS as the global reference for its product. The SmPC is the text approved in a given European market. These are not the same document, they drift apart over time, and knowing which text governs which assessment in which territory is a standing operational question rather than a solved one.
The second is that the flow runs both ways. Signals confirmed through signal management, or conclusions reached in a periodic safety update report, feed back into the SmPC through variations to sections 4.4 and 4.8. The SmPC is simultaneously the input to expectedness assessment and the output of the safety review cycle.
The practical implication is easy to state and hard to operationalise: an expectedness assessment made against a superseded version of section 4.8 is an assessment made against the wrong document.
Which leads to the property that most explanations of the SmPC omit entirely.
An SmPC is not issued once. It changes across the entire lifecycle of the product, through variations governed by Regulation (EC) No 1234/2008, as new safety data accumulate, indications are added or restricted, and pharmacological understanding develops. Section 10, Date of revision of the text, exists precisely because the document has versions.
So "the SmPC" almost always means "the current version of the SmPC", and the current version is a moving target. Now multiply that across markets. The same active substance authorised nationally in several countries has a separate SmPC in each, each on its own revision cycle, each in its own language, each published by a different national competent authority. There is no single consolidated source that holds all of them in their current state.
That is not a complaint about regulators. It is a direct consequence of a system in which national authorisations are genuinely national. But it does mean that the question "what does the SmPC say" is, in a multi-country setting, considerably harder than it sounds.
The regulatory network's answer to that problem is electronic product information, or ePI. The EMA defines it as "the authorised, statutory product information for medicines (including the summary of product characteristics, package leaflet and labelling) adapted for handling in electronic format and dissemination via the web, e-platforms and in print".
The mechanics matter for anyone building systems against this data. The EU ePI Common Standard is based on HL7 FHIR, and it has been adopted by the European medicines regulatory network. A pilot ran from July 2023 to August 2024 through the PLM Portal, with results published in December 2024.
Where it stands as of July 2026: a draft implementation roadmap was published in March 2026, setting out a phased rollout that begins with vaccines (ATC J07) on a voluntary basis in Q3 2026, extends to oncology (ATC L01 and L04) in Q4 2026, and progresses through other therapeutic areas, with centrally authorised products preceding national rollout. The EMA Management Board confirmed in March 2026 that ePI will become mandatory for newly authorised medicines once the new pharmaceutical legislation takes effect.
ePI is currently voluntary but strongly encouraged. It is not mandatory in 2026, and any source telling you otherwise is ahead of the facts. The direction of travel, however, is unambiguous: the SmPC is becoming structured, queryable data rather than a document you open and read.
For centrally authorised medicines, SmPCs are published by the European Medicines Agency. For nationally authorised medicines, each SmPC is published by the national competent authority of the country concerned.
For a single product in a single market, that is straightforward. The difficulty scales with breadth: track one active substance across a dozen markets, each with its own authority, its own revision cadence and its own language, and the retrieval problem becomes the actual work. The bottleneck is rarely finding an SmPC. It is knowing whether the copy in front of you is current, and what the equivalent text says in the market next door.
That is the problem pharmazie.com was built for. It consolidates SmPC full texts alongside more than 25 pharmaceutical databases in a single search across Germany, the DACH region and over 50 countries, and ChatSmPC® lets you query those full texts directly rather than reading through them.
This content is intended for healthcare professionals and does not constitute medical advice. Last reviewed: July 2026.
